nodes	percent_of_prediction	percent_of_DWPC	metapath
Clindamycin—CYP3A4—Cytarabine—lymphatic system cancer	0.181	0.318	CbGbCtD
Clindamycin—CYP3A4—Teniposide—lymphatic system cancer	0.178	0.313	CbGbCtD
Clindamycin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.124	0.219	CbGbCtD
Clindamycin—CYP3A4—Vincristine—lymphatic system cancer	0.0856	0.151	CbGbCtD
Clindamycin—Proteinuria—Fludarabine—lymphatic system cancer	0.00485	0.0112	CcSEcCtD
Clindamycin—Protein urine present—Fludarabine—lymphatic system cancer	0.00478	0.0111	CcSEcCtD
Clindamycin—Local reaction—Mitoxantrone—lymphatic system cancer	0.00458	0.0106	CcSEcCtD
Clindamycin—Sunburn—Methotrexate—lymphatic system cancer	0.00418	0.00968	CcSEcCtD
Clindamycin—Taste metallic—Methotrexate—lymphatic system cancer	0.00397	0.0092	CcSEcCtD
Clindamycin—Oesophagitis—Fludarabine—lymphatic system cancer	0.00389	0.00901	CcSEcCtD
Clindamycin—Abdominal cramps—Vincristine—lymphatic system cancer	0.00385	0.00893	CcSEcCtD
Clindamycin—Menstrual disorder—Mitoxantrone—lymphatic system cancer	0.00372	0.00861	CcSEcCtD
Clindamycin—Jaundice—Mechlorethamine—lymphatic system cancer	0.00358	0.0083	CcSEcCtD
Clindamycin—Tenderness—Bleomycin—lymphatic system cancer	0.00358	0.00829	CcSEcCtD
Clindamycin—Abscess—Carmustine—lymphatic system cancer	0.00344	0.00798	CcSEcCtD
Clindamycin—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00343	0.00795	CcSEcCtD
Clindamycin—Ulcer—Bleomycin—lymphatic system cancer	0.0033	0.00765	CcSEcCtD
Clindamycin—Fungal infection—Mitoxantrone—lymphatic system cancer	0.00328	0.0076	CcSEcCtD
Clindamycin—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00312	0.00723	CcSEcCtD
Clindamycin—Skin exfoliation—Bleomycin—lymphatic system cancer	0.00298	0.00691	CcSEcCtD
Clindamycin—Leukocytosis—Carmustine—lymphatic system cancer	0.0029	0.00672	CcSEcCtD
Clindamycin—Proteinuria—Mitoxantrone—lymphatic system cancer	0.00288	0.00668	CcSEcCtD
Clindamycin—Protein urine present—Mitoxantrone—lymphatic system cancer	0.00284	0.00659	CcSEcCtD
Clindamycin—Neutropenia—Teniposide—lymphatic system cancer	0.00284	0.00658	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00278	0.00645	CcSEcCtD
Clindamycin—Bacterial infection—Methotrexate—lymphatic system cancer	0.00273	0.00633	CcSEcCtD
Clindamycin—Ulcer—Mitoxantrone—lymphatic system cancer	0.00268	0.00621	CcSEcCtD
Clindamycin—Candida infection—Carmustine—lymphatic system cancer	0.0026	0.00603	CcSEcCtD
Clindamycin—Skin exfoliation—Carmustine—lymphatic system cancer	0.0026	0.00603	CcSEcCtD
Clindamycin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00258	0.00598	CcSEcCtD
Clindamycin—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00257	0.00596	CcSEcCtD
Clindamycin—Dysuria—Fludarabine—lymphatic system cancer	0.0025	0.00579	CcSEcCtD
Clindamycin—Neutropenia—Fludarabine—lymphatic system cancer	0.0025	0.00579	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00248	0.00575	CcSEcCtD
Clindamycin—Azotaemia—Methotrexate—lymphatic system cancer	0.00237	0.00549	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00236	0.00547	CcSEcCtD
Clindamycin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00234	0.00543	CcSEcCtD
Clindamycin—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00232	0.00536	CcSEcCtD
Clindamycin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0023	0.00532	CcSEcCtD
Clindamycin—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00229	0.00529	CcSEcCtD
Clindamycin—Flushing—Teniposide—lymphatic system cancer	0.00226	0.00523	CcSEcCtD
Clindamycin—Epistaxis—Fludarabine—lymphatic system cancer	0.00225	0.0052	CcSEcCtD
Clindamycin—Swelling—Carmustine—lymphatic system cancer	0.00224	0.00519	CcSEcCtD
Clindamycin—Swelling—Mitoxantrone—lymphatic system cancer	0.00208	0.00483	CcSEcCtD
Clindamycin—Vaginal discharge—Methotrexate—lymphatic system cancer	0.00207	0.00481	CcSEcCtD
Clindamycin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00202	0.00468	CcSEcCtD
Clindamycin—Folliculitis—Methotrexate—lymphatic system cancer	0.00201	0.00465	CcSEcCtD
Clindamycin—Anaemia—Teniposide—lymphatic system cancer	0.00196	0.00453	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0019	0.0044	CcSEcCtD
Clindamycin—Leukopenia—Teniposide—lymphatic system cancer	0.0019	0.00439	CcSEcCtD
Clindamycin—Hypertension—Teniposide—lymphatic system cancer	0.00183	0.00424	CcSEcCtD
Clindamycin—Cardiac arrest—Vincristine—lymphatic system cancer	0.0018	0.00416	CcSEcCtD
Clindamycin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00173	0.004	CcSEcCtD
Clindamycin—Anaemia—Fludarabine—lymphatic system cancer	0.00172	0.00399	CcSEcCtD
Clindamycin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00169	0.00392	CcSEcCtD
Clindamycin—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00168	0.00389	CcSEcCtD
Clindamycin—Leukopenia—Fludarabine—lymphatic system cancer	0.00167	0.00386	CcSEcCtD
Clindamycin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00166	0.00384	CcSEcCtD
Clindamycin—Fungal infection—Methotrexate—lymphatic system cancer	0.00163	0.00379	CcSEcCtD
Clindamycin—Hypotension—Teniposide—lymphatic system cancer	0.00162	0.00374	CcSEcCtD
Clindamycin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0016	0.00372	CcSEcCtD
Clindamycin—Neutropenia—Carmustine—lymphatic system cancer	0.0016	0.0037	CcSEcCtD
Clindamycin—Abscess—Methotrexate—lymphatic system cancer	0.0016	0.0037	CcSEcCtD
Clindamycin—Discomfort—Fludarabine—lymphatic system cancer	0.00157	0.00363	CcSEcCtD
Clindamycin—Dyspnoea—Teniposide—lymphatic system cancer	0.00154	0.00357	CcSEcCtD
Clindamycin—Dysuria—Vincristine—lymphatic system cancer	0.00153	0.00354	CcSEcCtD
Clindamycin—Neutropenia—Vincristine—lymphatic system cancer	0.00153	0.00354	CcSEcCtD
Clindamycin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00152	0.00352	CcSEcCtD
Clindamycin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00149	0.00345	CcSEcCtD
Clindamycin—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00149	0.00345	CcSEcCtD
Clindamycin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00149	0.00345	CcSEcCtD
Clindamycin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00149	0.00344	CcSEcCtD
Clindamycin—Urinary tract infection—Carmustine—lymphatic system cancer	0.00148	0.00343	CcSEcCtD
Clindamycin—Rash—Mechlorethamine—lymphatic system cancer	0.00148	0.00342	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00148	0.00342	CcSEcCtD
Clindamycin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00148	0.00342	CcSEcCtD
Clindamycin—Flushing—Bleomycin—lymphatic system cancer	0.00146	0.00337	CcSEcCtD
Clindamycin—Proteinuria—Methotrexate—lymphatic system cancer	0.00144	0.00333	CcSEcCtD
Clindamycin—Protein urine present—Methotrexate—lymphatic system cancer	0.00142	0.00328	CcSEcCtD
Clindamycin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00141	0.00327	CcSEcCtD
Clindamycin—Nausea—Mechlorethamine—lymphatic system cancer	0.00139	0.00323	CcSEcCtD
Clindamycin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00138	0.0032	CcSEcCtD
Clindamycin—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00138	0.00319	CcSEcCtD
Clindamycin—Urticaria—Teniposide—lymphatic system cancer	0.00137	0.00318	CcSEcCtD
Clindamycin—Oliguria—Methotrexate—lymphatic system cancer	0.00137	0.00317	CcSEcCtD
Clindamycin—Body temperature increased—Teniposide—lymphatic system cancer	0.00137	0.00317	CcSEcCtD
Clindamycin—Abdominal pain—Teniposide—lymphatic system cancer	0.00137	0.00317	CcSEcCtD
Clindamycin—Erythema—Bleomycin—lymphatic system cancer	0.00136	0.00316	CcSEcCtD
Clindamycin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00135	0.00314	CcSEcCtD
Clindamycin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00134	0.0031	CcSEcCtD
Clindamycin—Ulcer—Methotrexate—lymphatic system cancer	0.00133	0.00309	CcSEcCtD
Clindamycin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00132	0.00306	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00131	0.00304	CcSEcCtD
Clindamycin—Fatigue—Fludarabine—lymphatic system cancer	0.00131	0.00303	CcSEcCtD
Clindamycin—Inflammation—Methotrexate—lymphatic system cancer	0.0013	0.00301	CcSEcCtD
Clindamycin—Pain—Fludarabine—lymphatic system cancer	0.0013	0.00301	CcSEcCtD
Clindamycin—Constipation—Fludarabine—lymphatic system cancer	0.0013	0.00301	CcSEcCtD
Clindamycin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00127	0.00295	CcSEcCtD
Clindamycin—Flushing—Carmustine—lymphatic system cancer	0.00127	0.00294	CcSEcCtD
Clindamycin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00126	0.00292	CcSEcCtD
Clindamycin—Anaemia—Bleomycin—lymphatic system cancer	0.00126	0.00292	CcSEcCtD
Clindamycin—Asthenia—Teniposide—lymphatic system cancer	0.00124	0.00287	CcSEcCtD
Clindamycin—Pruritus—Teniposide—lymphatic system cancer	0.00122	0.00283	CcSEcCtD
Clindamycin—Leukopenia—Bleomycin—lymphatic system cancer	0.00122	0.00283	CcSEcCtD
Clindamycin—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00121	0.00279	CcSEcCtD
Clindamycin—Body temperature increased—Fludarabine—lymphatic system cancer	0.0012	0.00278	CcSEcCtD
Clindamycin—Vaginal infection—Methotrexate—lymphatic system cancer	0.00119	0.00276	CcSEcCtD
Clindamycin—Erythema—Carmustine—lymphatic system cancer	0.00119	0.00276	CcSEcCtD
Clindamycin—Diarrhoea—Teniposide—lymphatic system cancer	0.00118	0.00274	CcSEcCtD
Clindamycin—Back pain—Carmustine—lymphatic system cancer	0.00115	0.00267	CcSEcCtD
Clindamycin—Discomfort—Bleomycin—lymphatic system cancer	0.00115	0.00266	CcSEcCtD
Clindamycin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00112	0.00259	CcSEcCtD
Clindamycin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00111	0.00258	CcSEcCtD
Clindamycin—Erythema—Mitoxantrone—lymphatic system cancer	0.00111	0.00257	CcSEcCtD
Clindamycin—Anaemia—Carmustine—lymphatic system cancer	0.0011	0.00255	CcSEcCtD
Clindamycin—Back pain—Vincristine—lymphatic system cancer	0.0011	0.00255	CcSEcCtD
Clindamycin—Vomiting—Teniposide—lymphatic system cancer	0.0011	0.00255	CcSEcCtD
Clindamycin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00109	0.00253	CcSEcCtD
Clindamycin—Asthenia—Fludarabine—lymphatic system cancer	0.00109	0.00253	CcSEcCtD
Clindamycin—Rash—Teniposide—lymphatic system cancer	0.00109	0.00252	CcSEcCtD
Clindamycin—Dermatitis—Teniposide—lymphatic system cancer	0.00109	0.00252	CcSEcCtD
Clindamycin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00108	0.00251	CcSEcCtD
Clindamycin—Headache—Teniposide—lymphatic system cancer	0.00108	0.00251	CcSEcCtD
Clindamycin—Pruritus—Fludarabine—lymphatic system cancer	0.00107	0.00249	CcSEcCtD
Clindamycin—Back pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00248	CcSEcCtD
Clindamycin—Leukopenia—Carmustine—lymphatic system cancer	0.00107	0.00247	CcSEcCtD
Clindamycin—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00106	0.00245	CcSEcCtD
Clindamycin—Anaemia—Vincristine—lymphatic system cancer	0.00105	0.00244	CcSEcCtD
Clindamycin—Hypotension—Bleomycin—lymphatic system cancer	0.00104	0.00241	CcSEcCtD
Clindamycin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00104	0.00241	CcSEcCtD
Clindamycin—Hypertension—Carmustine—lymphatic system cancer	0.00103	0.00238	CcSEcCtD
Clindamycin—Nausea—Teniposide—lymphatic system cancer	0.00103	0.00238	CcSEcCtD
Clindamycin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00102	0.00237	CcSEcCtD
Clindamycin—Vertigo—Vincristine—lymphatic system cancer	0.00102	0.00237	CcSEcCtD
Clindamycin—Leukopenia—Vincristine—lymphatic system cancer	0.00102	0.00236	CcSEcCtD
Clindamycin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000993	0.0023	CcSEcCtD
Clindamycin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000991	0.0023	CcSEcCtD
Clindamycin—Hypertension—Vincristine—lymphatic system cancer	0.000982	0.00227	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000971	0.00225	CcSEcCtD
Clindamycin—Vomiting—Fludarabine—lymphatic system cancer	0.000966	0.00224	CcSEcCtD
Clindamycin—Rash—Fludarabine—lymphatic system cancer	0.000958	0.00222	CcSEcCtD
Clindamycin—Dermatitis—Fludarabine—lymphatic system cancer	0.000957	0.00222	CcSEcCtD
Clindamycin—Hypertension—Mitoxantrone—lymphatic system cancer	0.000956	0.00222	CcSEcCtD
Clindamycin—Pain—Bleomycin—lymphatic system cancer	0.000952	0.00221	CcSEcCtD
Clindamycin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000952	0.00221	CcSEcCtD
Clindamycin—Headache—Fludarabine—lymphatic system cancer	0.000952	0.0022	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000947	0.00219	CcSEcCtD
Clindamycin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000932	0.00216	CcSEcCtD
Clindamycin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000928	0.00215	CcSEcCtD
Clindamycin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000909	0.00211	CcSEcCtD
Clindamycin—Hypotension—Carmustine—lymphatic system cancer	0.000909	0.0021	CcSEcCtD
Clindamycin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000904	0.00209	CcSEcCtD
Clindamycin—Nausea—Fludarabine—lymphatic system cancer	0.000902	0.00209	CcSEcCtD
Clindamycin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000885	0.00205	CcSEcCtD
Clindamycin—Urticaria—Bleomycin—lymphatic system cancer	0.000885	0.00205	CcSEcCtD
Clindamycin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000881	0.00204	CcSEcCtD
Clindamycin—Hypotension—Vincristine—lymphatic system cancer	0.000867	0.00201	CcSEcCtD
Clindamycin—Dyspnoea—Carmustine—lymphatic system cancer	0.000867	0.00201	CcSEcCtD
Clindamycin—Hypotension—Mitoxantrone—lymphatic system cancer	0.000845	0.00196	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000839	0.00194	CcSEcCtD
Clindamycin—Pain—Carmustine—lymphatic system cancer	0.000831	0.00193	CcSEcCtD
Clindamycin—Constipation—Carmustine—lymphatic system cancer	0.000831	0.00193	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000825	0.00191	CcSEcCtD
Clindamycin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000821	0.0019	CcSEcCtD
Clindamycin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000806	0.00187	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000801	0.00186	CcSEcCtD
Clindamycin—Fatigue—Vincristine—lymphatic system cancer	0.0008	0.00185	CcSEcCtD
Clindamycin—Asthenia—Bleomycin—lymphatic system cancer	0.000799	0.00185	CcSEcCtD
Clindamycin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000796	0.00184	CcSEcCtD
Clindamycin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000795	0.00184	CcSEcCtD
Clindamycin—Constipation—Vincristine—lymphatic system cancer	0.000794	0.00184	CcSEcCtD
Clindamycin—Pain—Vincristine—lymphatic system cancer	0.000794	0.00184	CcSEcCtD
Clindamycin—Pruritus—Bleomycin—lymphatic system cancer	0.000788	0.00183	CcSEcCtD
Clindamycin—Eosinophilia—Methotrexate—lymphatic system cancer	0.000784	0.00182	CcSEcCtD
Clindamycin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000779	0.00181	CcSEcCtD
Clindamycin—Pain—Mitoxantrone—lymphatic system cancer	0.000773	0.00179	CcSEcCtD
Clindamycin—Constipation—Mitoxantrone—lymphatic system cancer	0.000773	0.00179	CcSEcCtD
Clindamycin—Abdominal pain—Carmustine—lymphatic system cancer	0.000769	0.00178	CcSEcCtD
Clindamycin—Body temperature increased—Carmustine—lymphatic system cancer	0.000769	0.00178	CcSEcCtD
Clindamycin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000759	0.00176	CcSEcCtD
Clindamycin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000759	0.00176	CcSEcCtD
Clindamycin—Dysuria—Methotrexate—lymphatic system cancer	0.000741	0.00172	CcSEcCtD
Clindamycin—Neutropenia—Methotrexate—lymphatic system cancer	0.000741	0.00172	CcSEcCtD
Clindamycin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000739	0.00171	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000736	0.00171	CcSEcCtD
Clindamycin—Body temperature increased—Vincristine—lymphatic system cancer	0.000734	0.0017	CcSEcCtD
Clindamycin—Abdominal pain—Vincristine—lymphatic system cancer	0.000734	0.0017	CcSEcCtD
Clindamycin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000723	0.00167	CcSEcCtD
Clindamycin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000718	0.00166	CcSEcCtD
Clindamycin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000716	0.00166	CcSEcCtD
Clindamycin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000715	0.00166	CcSEcCtD
Clindamycin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000715	0.00166	CcSEcCtD
Clindamycin—Vomiting—Bleomycin—lymphatic system cancer	0.000708	0.00164	CcSEcCtD
Clindamycin—Rash—Bleomycin—lymphatic system cancer	0.000702	0.00163	CcSEcCtD
Clindamycin—Dermatitis—Bleomycin—lymphatic system cancer	0.000702	0.00163	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0007	0.00162	CcSEcCtD
Clindamycin—Asthenia—Carmustine—lymphatic system cancer	0.000698	0.00162	CcSEcCtD
Clindamycin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000684	0.00158	CcSEcCtD
Clindamycin—Epistaxis—Methotrexate—lymphatic system cancer	0.000666	0.00154	CcSEcCtD
Clindamycin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000666	0.00154	CcSEcCtD
Clindamycin—Asthenia—Vincristine—lymphatic system cancer	0.000666	0.00154	CcSEcCtD
Clindamycin—Diarrhoea—Carmustine—lymphatic system cancer	0.000665	0.00154	CcSEcCtD
Clindamycin—Nausea—Bleomycin—lymphatic system cancer	0.000662	0.00153	CcSEcCtD
Clindamycin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000659	0.00153	CcSEcCtD
Clindamycin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000649	0.0015	CcSEcCtD
Clindamycin—Dizziness—Carmustine—lymphatic system cancer	0.000643	0.00149	CcSEcCtD
Clindamycin—Diarrhoea—Vincristine—lymphatic system cancer	0.000635	0.00147	CcSEcCtD
Clindamycin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000618	0.00143	CcSEcCtD
Clindamycin—Vomiting—Carmustine—lymphatic system cancer	0.000618	0.00143	CcSEcCtD
Clindamycin—Dizziness—Vincristine—lymphatic system cancer	0.000614	0.00142	CcSEcCtD
Clindamycin—Rash—Carmustine—lymphatic system cancer	0.000613	0.00142	CcSEcCtD
Clindamycin—Dermatitis—Carmustine—lymphatic system cancer	0.000612	0.00142	CcSEcCtD
Clindamycin—Headache—Carmustine—lymphatic system cancer	0.000609	0.00141	CcSEcCtD
Clindamycin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000599	0.00139	CcSEcCtD
Clindamycin—Vomiting—Vincristine—lymphatic system cancer	0.00059	0.00137	CcSEcCtD
Clindamycin—Rash—Vincristine—lymphatic system cancer	0.000585	0.00136	CcSEcCtD
Clindamycin—Dermatitis—Vincristine—lymphatic system cancer	0.000585	0.00135	CcSEcCtD
Clindamycin—Headache—Vincristine—lymphatic system cancer	0.000581	0.00135	CcSEcCtD
Clindamycin—Nausea—Carmustine—lymphatic system cancer	0.000578	0.00134	CcSEcCtD
Clindamycin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000575	0.00133	CcSEcCtD
Clindamycin—Rash—Mitoxantrone—lymphatic system cancer	0.00057	0.00132	CcSEcCtD
Clindamycin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000569	0.00132	CcSEcCtD
Clindamycin—Headache—Mitoxantrone—lymphatic system cancer	0.000566	0.00131	CcSEcCtD
Clindamycin—Erythema—Methotrexate—lymphatic system cancer	0.000552	0.00128	CcSEcCtD
Clindamycin—Nausea—Vincristine—lymphatic system cancer	0.000551	0.00128	CcSEcCtD
Clindamycin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00054	0.00125	CcSEcCtD
Clindamycin—Nausea—Mitoxantrone—lymphatic system cancer	0.000537	0.00124	CcSEcCtD
Clindamycin—Back pain—Methotrexate—lymphatic system cancer	0.000534	0.00124	CcSEcCtD
Clindamycin—Anaemia—Methotrexate—lymphatic system cancer	0.00051	0.00118	CcSEcCtD
Clindamycin—Vertigo—Methotrexate—lymphatic system cancer	0.000496	0.00115	CcSEcCtD
Clindamycin—Leukopenia—Methotrexate—lymphatic system cancer	0.000494	0.00114	CcSEcCtD
Clindamycin—Discomfort—Methotrexate—lymphatic system cancer	0.000464	0.00108	CcSEcCtD
Clindamycin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00045	0.00104	CcSEcCtD
Clindamycin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000441	0.00102	CcSEcCtD
Clindamycin—Hypotension—Methotrexate—lymphatic system cancer	0.000421	0.000975	CcSEcCtD
Clindamycin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000401	0.00093	CcSEcCtD
Clindamycin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000396	0.000918	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000389	0.000901	CcSEcCtD
Clindamycin—Fatigue—Methotrexate—lymphatic system cancer	0.000388	0.000899	CcSEcCtD
Clindamycin—Pain—Methotrexate—lymphatic system cancer	0.000385	0.000892	CcSEcCtD
Clindamycin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000368	0.000853	CcSEcCtD
Clindamycin—Urticaria—Methotrexate—lymphatic system cancer	0.000358	0.000829	CcSEcCtD
Clindamycin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000356	0.000825	CcSEcCtD
Clindamycin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000356	0.000825	CcSEcCtD
Clindamycin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000332	0.000769	CcSEcCtD
Clindamycin—Asthenia—Methotrexate—lymphatic system cancer	0.000323	0.000749	CcSEcCtD
Clindamycin—Pruritus—Methotrexate—lymphatic system cancer	0.000319	0.000738	CcSEcCtD
Clindamycin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000308	0.000714	CcSEcCtD
Clindamycin—Dizziness—Methotrexate—lymphatic system cancer	0.000298	0.00069	CcSEcCtD
Clindamycin—Vomiting—Methotrexate—lymphatic system cancer	0.000286	0.000663	CcSEcCtD
Clindamycin—Rash—Methotrexate—lymphatic system cancer	0.000284	0.000658	CcSEcCtD
Clindamycin—Dermatitis—Methotrexate—lymphatic system cancer	0.000284	0.000657	CcSEcCtD
Clindamycin—Headache—Methotrexate—lymphatic system cancer	0.000282	0.000654	CcSEcCtD
Clindamycin—Nausea—Methotrexate—lymphatic system cancer	0.000267	0.00062	CcSEcCtD
